Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes
Abstract
Cancer vaccines may be harnessed to incite immunity against poorly immunogenic tumors, however they have failed in therapeutic settings. Poor antigenicity coupled with systemic and intratumoral immune suppression have been significant drawbacks. RNA encoding for tumor associated or specific epitopes can serve as a more immunogenic and expeditious trigger of anti-tumor immunity. RNA stimulates innate immunity through toll like receptor stimulation producing type I interferon, and it mediates potent adaptive responses. Since RNA is inherently unstable, delivery systems have been developed to protect and deliver it to intended targets in vivo. In this review, we discuss liposomes as RNA delivery vehicles and their role as cancer vaccines.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 23, 2018
- Source ID
- 10.3390/ijms19102890
Entities
People
- Duane A Mitchell
- Elias J Sayour
- Hector Mendez-gomez
Organizations
- Foundation for the National Institutes of Health
- St. Baldrick's Foundation
- United States Department of Defense